Erste Asset Management’s Keros Therapeutics KROS Stock Holding History

Erste Asset Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-41,400	Closed	-$660K	–	638
2025 Q3	$660K	Buy	41,400 +20,700	+100%	+$306K	0.01%	448
2025 Q2	$279K	Hold	20,700	–	–	﹤0.01%	717
2025 Q1	$223K	Hold	20,700	–	–	﹤0.01%	469
2024 Q4	$340K	Hold	20,700	–	–	﹤0.01%	466
2024 Q3	$1.17M	Hold	20,700	–	–	0.01%	376
2024 Q2	$933K	Hold	20,700	–	–	0.01%	378
2024 Q1	$1.34M	Buy	20,700 +15,000	+263%	+$889K	0.02%	343
2023 Q4	$234K	Hold	5,700	–	–	﹤0.01%	479
2023 Q3	$186K	Hold	5,700	–	–	﹤0.01%	483
2023 Q2	$227K	Hold	5,700	–	–	﹤0.01%	483
2023 Q1	$240K	Hold	5,700	–	–	﹤0.01%	479
2022 Q4	$274K	Hold	5,700	–	–	0.01%	465
2022 Q3	$207K	Hold	5,700	–	–	﹤0.01%	495
2022 Q2	$155K	Hold	5,700	–	–	﹤0.01%	528
2022 Q1	$306K	Hold	5,700	–	–	0.01%	478
2021 Q4	$318K	Hold	5,700	–	–	0.01%	470
2021 Q3	$234K	Hold	5,700	–	–	﹤0.01%	468
2021 Q2	$242K	Hold	5,700	–	–	﹤0.01%	464
2021 Q1	$328K	Hold	5,700	–	–	0.01%	421
2020 Q4	$425K	Buy	+5,700	New	+$359K	0.01%	402

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Erste Asset Management's KROS Position: Q4 2025 in Review

Erste Asset Management sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 41,400 shares — an estimated $660K sold.

Erste Asset Management first reported a position in KROS in Q4 2020 and held it in 20 quarters. The position peaked at $1.34M in Q1 2024. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

Erste Asset Management reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
Erste Asset Management sold 41,400 Keros Therapeutics shares in Q4 2025, an estimated $660K.
Erste Asset Management first reported a position in Keros Therapeutics in Q4 2020 and held it in 20 quarters.
Erste Asset Management's Keros Therapeutics position peaked at $1.34M in Q1 2024.
166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on Erste Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.